It is expected that complement inhibitors, like sutimlimab (C1s inhibitor), which inhibit the complement cascade further upstream, may be more effective than eculizumab as they address extravascular haemolysis (the predominant form of haemolysis in CAD).1 This evidence concerns the gene C1S and cold agglutinin disease.